These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 3527304)

  • 1. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
    Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
    Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K; Jänicke F
    Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW
    Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
    Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
    Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
    Lønning PE; Geisler J; Johannessen DC; Ekse D
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
    Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
    Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
    Santner SJ; Feil PD; Santen RJ
    J Clin Endocrinol Metab; 1984 Jul; 59(1):29-33. PubMed ID: 6725522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of aromatase activity in human breast cancer.
    Miller WR; Hawkins RA; Forrest AP
    Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.